Valneva IPO Presentation Deck

VLA1553: Development Outlook Pivotal Phase 3 Trial - Topline Read-out Expected Mid-2021 ■ Phase 3 Clinical Development Program underway Pivotal Phase 3 safety and immunogenicity trial in 4,131 healthy volunteers fully enrolled¹ - - - Topline read-out on Day 29 (based on surrogate of protection) mid-2021 Lot-to-Lot consistency trial initiated (VLA1553-302) in ~400 volunteers² Antibody persistence follow-up trial initiated (VLA1553-303) - up to 375 volunteers from VLA1553-301 will be followed up annually for five years after a single immunization¹ Adolescents' clinical trial in 750 volunteers in Brazil planned to commence in 2021³ Accelerated approval pathway agreed with FDA4 ■ VLA1553 may be eligible for Priority Review Voucher upon FDA approval5 ¹ Vaineva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial 2 Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate. In collaboration with development partner Instituto Butantan, under CEPI funding. Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority- review-voucher-program Valneva - Roadshow Presentation April 2021 23

View entire presentation